CN108066339A - A kind of pharmaceutical composition of Parecoxib Sodium - Google Patents
A kind of pharmaceutical composition of Parecoxib Sodium Download PDFInfo
- Publication number
- CN108066339A CN108066339A CN201810137367.6A CN201810137367A CN108066339A CN 108066339 A CN108066339 A CN 108066339A CN 201810137367 A CN201810137367 A CN 201810137367A CN 108066339 A CN108066339 A CN 108066339A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- sodium
- present
- injection
- parecoxib sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of pharmaceutical compositions of Parecoxib Sodium, belong to field of medicaments.SC 69124 is as dosage and exposure duration increase and increase during analgesia, and long-time service is then present with the rise of liver transaminases, so as to influence the clinical application range of drug.In order to overcome the technical deficiency of erious adverse reaction during analgesia therapy in the prior art; the present invention provides a kind of for analgesic pharmaceutical composition; it is using Parecoxib Sodium and ginkgolides as active constituents of medicine; when the pharmaceutical composition is used for analgesia therapy; two kinds of active components have significant synergistic effect in ease pain; and the adverse reaction of drug can be significantly reduced, significant protective effect is especially embodied to liver, therefore suitable for developing into clinical treatment drug.
Description
Technical field
The present invention relates to a kind of pharmaceutical compositions of Parecoxib Sodium, belong to field of medicaments.
Background technology
Parecoxib Sodium, chemical name：N- [[4- (5- methyl -3- phenyl -4- isoxazolyls) phenyl] sulfonyl] propionyl
Amine sodium salt.Parecoxib Sodium be -2 acceptor inhibitor of injection-type selective COX-2, be Valdecoxib inactive precursor drug, town
Bitterly rapid-action, half-life short can not only inhibit periphery and maincenter COX-2 receptor actives, may also suppress the quick of periphery and maincenter
Change, generate good analgesic effect.
SC 69124 declares listing in March, 2002 by Pfizer in European Union, and trade name " special resistance to ", which is to cut down ground former times
The pro-drug of cloth.In May, 2008, Pfizer's injection Parecoxib Sodium list in China, and dosage form is powder-injection, and specification has two
Kind, it is respectively 20mg, 40mg.
From the point of view of sample hospital market, the enterprise into sample hospital data statistics in 2015 only has import enterprise 1, is
Pfizer subordinate's Pharmacia (Pharmacia) company.Domestic SC 69124 medication market scale is from 18,270,000 yuan of 2009 increasings
2.1 hundred million yuan in 2015 are grown to, 2009-2015 annual compound growth rates are 50.1%, which has kept higher since listing
Growth rate, but the product market in 2015 starts to slow down.
The recommended dose of Parecoxib Sodium is 40mg, is injected intravenously (IV) or intramuscular injection (IM) administration, then optionally
Interval 6-12 gives 20mg or 40mg when small, daily accumulated dose is no more than 80mg.Rapid intravenous bolus injection can directly be carried out or passed through
Has venous channel administration.Intramuscular injection should select deep part muscle slowly to inject.
It is limited using clinical experience of this drug more than three days at present.Opium kind analgesics can simultaneously should with SC 69124
With in all clinical assessments, SC 69124 is fixed interval administration, and opioid drug is then to be administered on demand.By
Mixedly appear precipitation in the solution in SC 69124 and other medicines, no matter therefore in dissolving or injection process, pa auspicious former times
Cloth is forbidden to mix with other medicines.As SC 69124 and other medicines use same venous channel, the injection of SC 69124 solution
It is front and rear venous channel fully to be rinsed using compatible solution.Occur additionally, due to the cardiovascular event of Selective COX-2 inhibitor
Therefore risk, should use most Low doses and minimum daily effective dose as far as possible as dosage and exposure duration increase and increase.
Therefore, the compatibility and its clinical practice risk of SC 69124 and other drugs are to expand SC 69124 clinical application range
Key factor.
《SC 69124 is analyzed in the Meta of backbone Postoperative Analgesia After curative effect》Related SC 69124 is collected in backbone Postoperative Analgesia After
Randomized controlled trial (RCT).By two researchers according to including and exclusion criteria screening document, extraction data and evaluation quality
Afterwards, Meta analyses are carried out using RevMan5.0 softwares.As a result：12 RCT are included altogether, totally 636 patients.Meta analysis results
Display：Postoperative 2,6,12,24,48h, for SC 69124 compared with placebo, VAS scorings have apparent heterogeneity (P<
0.05), difference on effect is statistically significant.Conclusion：SC 69124 can reach satisfied analgesic effect in backbone Postoperative Analgesia After,
The postoperative Conventional analgesics treatment of backbone can be used as.
The content of the invention
For SC 69124 as dosage and exposure duration increase and increase during analgesia, long-time service is then present with liver
The rise of transaminase, so as to influence the clinical application range of drug.It is bad during analgesia therapy in the prior art in order to overcome
Big technical deficiency is reacted, the present invention provides one kind for analgesic pharmaceutical composition, with Parecoxib Sodium and ginkgolides
For active constituents of medicine, when the pharmaceutical composition is used for analgesia therapy, two kinds of active components have notable in ease pain
Synergistic effect, and the adverse reaction of drug can be significantly reduced, significant protective effect is especially embodied to liver, therefore suitable
Develop into clinical treatment drug.
An object of the present invention be to provide it is a kind of for analgesic pharmaceutical composition, said composition with Parecoxib Sodium with
Ginkgolides is active ingredient, is formed with pharmaceutically acceptable auxiliary material combination.
Test examples of the present invention show two kinds it is medication combined for easing pain, the pharmaceutical composition is controlled for easing pain
During treatment, two kinds of active component combinations not only have significant synergistic effect in ease pain, and can significantly reduce SC 69124
Adverse reaction, especially to preventing liver transaminases rise from embodying significant effect.
The weight ratio of Parecoxib Sodium and ginkgolides is 1 in the pharmaceutical composition:15-33.Further preferably
1:30。
The two of the object of the invention are to provide the pharmaceutical preparation comprising aforementioned pharmaceutical compositions.Aforementioned pharmaceutical compositions of the present invention
It is preferably freeze drying powder injection when pharmaceutical composition is used for clinical treatment.Specification is 3mL/ branch in the freeze drying powder injection, wherein excellent
The content of Parecoxib Sodium in per unit preparation is elected as 5mg-10mg, the content of ginkgolides is 0.5-5mg.
Prescription and content composition of the applicant also to the freeze drying powder injection comprising above-mentioned composition are screened, and work as drug
When composition is prepared into freeze drying powder injection, pharmaceutically acceptable auxiliary material can be mannitol, water for injection, sodium chloride, citric acid
Sodium, dextran, disodium hydrogen phosphate, sodium dihydrogen phosphate etc..Freeze drying powder injection described above can also be according to the property of drug
Suitable additives are added in, such as osmotic pressure regulator, pH adjusting agent, solubilizer, antioxidant, bacteriostatic agent, emulsifier, suspending agent
Deng.It has been found that when the freeze drying powder injection composition of pharmaceutical composition is as follows, the stability of pharmaceutical preparation is preferable.
The present invention also provides a kind of preparation methods of above-mentioned freeze drying powder injection, include the following steps：Distinguish by recipe quantity
Weigh Parecoxib Sodium, ginkgolides, mannitol.Mannitol is added in appropriate water for injection, stirring and dissolving and with 0.1%
(w/v) activated carbon adsorption, 0.45 μm of filter or filter membrane pre-filtering add in Parecoxib Sodium stirring and dissolving and are adjusted with sodium hydroxide
PH value is to 7.0-8.5, constant volume after 0.45 μm of filter or filter membrane pre-filtering, 0.45 μm and 0.22 μm of filter or filter membrane aseptic filtration
Afterwards, filling, half tamponade is freeze-dried to obtain the freeze drying powder injection of the present composition.
Third object of the present invention is a kind of medical usage that aforementioned pharmaceutical compositions are claimed, i.e., described drug
Purposes of the composition in analgesic is prepared.The liver that pharmaceutical composition of the present invention can reduce caused by chemotherapeutics turns ammonia
Enzyme raises, and has significant synergistic effect in ease pain, therefore can be used for clinical analgesia.For treating the disease
When, the preferential freeze drying powder injection described above using the present invention.
When pharmaceutical composition of the present invention is treated for chronic obstructive pulmonary disease, there is following technical advantage：
1) two kinds in pharmaceutical composition of the present invention are medication combined for easing pain, and not only have significant association in ease pain
Same-action, and detrimental effect of the chemotherapeutics for liver can be significantly reduced after drug combination.
2) damaged when existing clinical treatment drug SC 69124 has larger liver damage effect, especially long-term administration
Evil more very, drastically influences the therapeutic effect of drug.It plus can be with ginkgolides on the basis of analgesic SC 69124 is used
Significantly reduce the adverse reaction of drug so that the quality of life of patient is obviously improved.
3) present composition can make patient medication more convenient after being prepared into freeze drying powder injection, dosage precise control,
And the daily medication of pharmaceutical composition of the present invention is once so that the compliance of patient greatly improves, and medical expense is decreased obviously.
Specific embodiment
It is further illustrated the present invention below by way of specific embodiment, but those skilled in the art should be able to know, the implementation
Example does not limit protection scope of the present invention in any way.
The freeze drying powder injection of 1 pharmaceutical composition of the present invention of embodiment
Composition：
Preparation process：Weigh Parecoxib Sodium, ginkgolides, mannitol respectively by recipe quantity.Mannitol is added to suitable
Measure water for injection in, stirring and dissolving and use 0.1% (w/v) activated carbon adsorption, 0.45 μm of filter or filter membrane pre-filtering, addition pa it is auspicious
Former times cloth sodium stirring and dissolving simultaneously adjusts pH value to 7.0-8.5 with sodium hydroxide, constant volume after 0.45 μm of filter or filter membrane pre-filtering, and 0.45
μm and 0.22 μm of filter or filter membrane aseptic filtration after, filling, half tamponade is freeze-dried to obtain the jelly of the present composition
Dry powder injection.
The freeze drying powder injection of 2 pharmaceutical composition of the present invention of embodiment
Composition：
Preparation method is in addition to prescription is different, other same embodiment of the present invention 1.
The freeze drying powder injection of 3 pharmaceutical composition of the present invention of embodiment
Composition：
Preparation method is in addition to prescription is different, other same embodiment of the present invention 1.
The freeze drying powder injection of 4 pharmaceutical composition of the present invention of embodiment
Composition：
Preparation method is in addition to prescription is different, other same embodiment of the present invention 1.
The freeze drying powder injection of 5 pharmaceutical composition of the present invention of embodiment
Composition：
Preparation method is in addition to prescription is different, other same embodiment of the present invention 1.
The investigation experiment of 6 medicinal composition freezing-dried powder injection of the present invention of embodiment
1. trial-manufacture of sample
By the formulation and technology pilot sample four batches of 1-5 of the embodiment of the present invention, lot number is respectively：170506 (4146),
170508 (4220), 170510 (4301), 170512 (4187).Through four batches of samples is examined to meet the requirements.
2. the project of investigation
Freeze-dried powder study on the stability under the experiment of 2.1 strong illuminations and hot test
Sample is removed into outer packing, (lot number is for the medicinal composition freezing-dried powder injection of the present invention of full inspection of learning from else's experience qualification
170506) it is respectively placed under strong illumination (4500 ± 500Lx), high temperature (60 DEG C) and places 10 days, is taken respectively in the 5th day and 10 days
Sample, and compareed with 0 day with batch sample data, it the results are shown in Table 1, table 2.Content in wherein following experiments is two kinds of active components
Total content calculates.
High temperature (60 DEG C) result of the test of 1 medicinal composition freezing-dried powder injection of the present invention of table
Find out from result above, this product is removing outer packing, is placed 10 days under 60 DEG C of hot conditions, appearance character, pH
Value, related substance and content have no significant change.
Illumination (4500 ± 500Lx) result of the test of 2 medicinal composition freezing-dried powder injection of the present invention of table
Find out from result above, this product is removing outer packing, the related substance under the conditions of strong illumination (4500 ± 500Lx)
Content slightly raises, but still within prescribed limit.Freeze-dried powder is shown by illumination and high temperature factors influencing result of the test
Injection sample is basicly stable to heat, light, illustrates this product using general packaging, shading storage according to more than experimental result.
Freeze-dried powder stability test under 2.2 high humidity environments
Medicinal composition freezing-dried powder injection of the present invention (lot number 170506) Jing Guo full inspection qualification is respectively placed in 25 DEG C
(KNO containing saturation in the environment of relative humidity 90% ± 5%3In the drier of solution), it places 10 days, respectively at the 5th day and the
10 days sample, be detected, investigate its appearance character, pH value, content, in relation to substance, moisture in terms of variation, the results are shown in Table 3.
The accelerated test result of 3 medicinal composition freezing-dried powder injection of the present invention of table
Result of the test shows that compared with before experiment the pH value of this freeze drying powder injection is basicly stable, changes in normal range (NR)
It is interior, it is basicly stable in relation to substance and active constituent content.
2.3 long term test
By the medicinal composition freezing-dried powder injection of the present invention (lot number 170506) Jing Guo full inspection qualification at ambient temperature,
Every bottle adds in 0.9% sodium chloride injection 3ml and makes its dissolving, is uniformly mixed, is placed naturally under room temperature (25 DEG C), in 0,2,4,
6th, 8 it is small when the content of sampling detection solution, related substance and pH value, carry out stability of solution after the redissolution of preparation and investigate to test to grind
Study carefully.It the results are shown in Table 4.
The long-term test results of 4 medicinal composition freezing-dried powder injection of the present invention of table
Result of the test shows compared with before experiment, when 0-8 is small after this freeze drying powder injection redissolves in pH value it is basicly stable,
Variation is basicly stable in relation to substance and active constituent content in normal range (NR).
3. conclusion (of pressure testing)
It is tested and tied in more than influence factor by medicinal composition freezing-dried powder injection of the present invention prepared by preparation process of the present invention
Show in fruit under conditions of exposure experiments to light, hot test, high wet test, redissolution experiment, pH is basically stable at normal range (NR)
Interior variation, drug content variation are stablized, and related Substances variation has rise, but still within the scope of defined.Wherein according to
The freeze drying powder injection that the embodiment of the present invention 1 is prepared is stablized the most in terms of the variation of related substance and changes of contents, is this hair
Bright optimal embodiment.
The influence of mouse writhing number caused by 7 pharmaceutical composition Dichlorodiphenyl Acetate of the present invention of embodiment
1. animal packet and administration
Male ICR mouse 70, (20 ± 2) g are randomly divided into 7 groups by weight, and every group 10, specific grouping situation is as follows：
2. experimental method and data processing
Mouse peritoneal injects acetic acid, causes abdominal cavity large area and more lasting pain stimulation, and mouse is caused to generate torsion
Precursor reactant.After each dosage group administration 1h, 0.7% acetic acid normal saline solution 0.1ml/10g is injected intraperitoneally, record injects acetic acid certainly
The writhing response number that every mouse occurs in 20min after induced pain calculates the inhibitory rate of each administration group.
Inhibitory rate=[(control group writhing number-medicine group writhing number)/control group writhing number] × 100%
Experimental data withIt represents, variance analysis is carried out using SPSS15.0 softwares.
3. experimental result
Experimental result is shown in Table 1
The influence of mouse writhing number caused by 1 pharmaceutical composition Dichlorodiphenyl Acetate of the present invention of table
Compared with model group,*P ＜ 0.01；Compared with ginkgolides group,&&P ＜ 0.01；
Compared with SC 69124 group, P ＜ 0.01；Compared with high group of SC 69124,##P ＜ 0.01.
Experimental result as shown in Table 1 understands that ginkgolides and SC 69124 are inhibiting acetic acid in each composition treatment group
There is apparent synergistic effect, inhibiting rate is not only significantly better than two kinds of drug given alones in terms of caused mouse writhing number
The adduction of group, better than two kinds of Drug inhibition rates, the analgesic effect of pharmaceutical composition of the present invention are also significantly better than existing antalgesic
Object SC 69124.It is specific as follows：
(1) compared with model group, each treatment group significantly inhibits work to writhing mouse writhing number caused by mouse acetic acid
With.
(2) compared with ginkgolides, SC 69124 independent medication, pharmaceutical composition group of the present invention has writhing inhibitory action
Pole significant difference (P<0.01), two medicines of display are shared with synergistic effect, and two medicines share and reaching the same of equivalent effect
When, each single pharmaceutical quantities can be significantly reduced, and then reduce the generation of adverse reaction.
(3) compared with SC 69124 group, pharmaceutical composition group of the present invention has writhing inhibitory action pole significant difference (P<
0.01), the pharmaceutical composition analgesic effect is more preferable.
The influence that 8 pharmaceutical composition of the present invention of embodiment reacts mouse hot-plate induced pain
1. animal packet and administration
Female ICR mice (20 ± 2) g is put on 55 ± 0.5 DEG C of intelligent hot-plate instrument, record mouse vola contact hot plate
It is pain indicator to the incubation period (s) for occurring licking metapedes reaction, rejects response latency ＜ 5s or the mouse of ＞ 30s or jump.
Qualified mouse of 70 response latencies in 10~30s is chosen, 7 groups are randomly divided into according to the preceding threshold of pain of medicine and weight, by as follows
Administration：
2. experimental method and data processing
Continuous gavage is administered 5 days, in 30 after administration, 60,90,120min when measure the threshold of pain 1 of each administration group mouse respectively
Secondary, pain threshold is calculated more than 60s person with 60s.
Data withIt represents, variance analysis is carried out using SPSS15.0 softwares.
3. experimental result
Experimental result is shown in Table 2
The influence that 2 pharmaceutical composition of the present invention of table reacts mouse hot-plate induced pain
Compared with model group,*P ＜ 0.05,*P ＜ 0.01；Compared with ginkgolides group,&&P ＜ 0.01；
Compared with SC 69124 group,#P ＜ 0.05.
From 2 experimental result of table, each administration group can improve the effect of the threshold of pain of mouse compared with model group, wherein silver
Apricot lactone and SC 69124 have significant synergistic effect in terms of the mouse threshold of pain is improved, and the threshold of pain of composition A, B, C group is improved
The adduction that better than two kinds drugs of effect are used alone, threshold of pain improvement effect is close with SC 69124, and wherein composition C groups and pa is auspicious
Former times cloth group, which is compared, has significant difference.It is specific as follows：
(1) compared with model group, each treatment group significantly inhibits effect to hot plate induced pain mice pain.
(2) compared with ginkgolides, SC 69124 independent medication, pharmaceutical composition group of the present invention inhibits to make to hot-plate model
With there is pole significant difference (P<0.01), two medicines of display are shared with synergistic effect, and two medicines share can significantly reduce it is each
Single pharmaceutical quantities, and then reduce the generation of adverse reaction.
(3) compared with SC 69124 group, pharmaceutical composition group of the present invention has significant difference to hot plate induced pain inhibitory action
(P<0.05), the pharmaceutical composition is more preferable to the analgesic effect of hot plate induced pain.
Influence of 3 pharmaceutical composition of table to serum transaminase ALT and AST content
| Group | n | ALT(U/L) | AST(U/L) |
| Normal group | 20 | 66.21±7.13 | 78.25±7.96 |
| Model group | 20 | 536.74±22.36** | 658.65±35.19** |
| High group of SC 69124 | 20 | 732.36±242.83*** | 1052.68±35.62*** |
| High group of ginkgolides | 20 | 498.36±34.16 | 550.49±32.16 |
| Composition A groups | 20 | 619.18±25.16▲ | 752.16±16.15▲ |
| Composition B groups | 20 | 567.34±24.39▲▲ | 685.32±26.14▲▲ |
| Composition C groups | 20 | 389.62±11.07▲▲ | 521.21±32.15▲▲ |
Compared with normal group,**P ＜ 0.01,***P ＜ 0.01；Compared with model group,#P ＜ 0.05,##P ＜ 0.01；
Compared with SC 69124 group,▲P ＜ 0.05,▲▲P ＜ 0.01；
As can be seen from the above table, ALT the and AST contents of model group have significant difference, pa auspicious former times compared with normal group
ALT the and AST contents of cloth group are compared with normal group with significant difference, are shown more tight to the hepar damnification of rat after medication
Weight.After being combined ginkgolides, the transaminase of pharmaceutical composition each group has compared with SC 69124 group to be remarkably decreased, this shows this
Invention pharmaceutical composition has good liver protection.
Although above the present invention is described in detail with a general description of the specific embodiments,
On the basis of the present invention, it can be modified or improved, this will be apparent to those skilled in the art, because
This, these modifications or improvements, belong to the scope of protection of the invention without departing from theon the basis of the spirit of the present invention.
Claims (9)
1. a kind of pharmaceutical composition of Parecoxib Sodium, which is characterized in that the active ingredient of described pharmaceutical composition is by pa auspicious former times
Cloth sodium and ginkgolides composition.
2. pharmaceutical composition as described in claim 1, which is characterized in that Parecoxib Sodium and ginkgo in described pharmaceutical composition
The weight ratio of lactone is 1:0.05-1.
3. pharmaceutical composition as claimed in claim 2, which is characterized in that Parecoxib Sodium and ginkgo in described pharmaceutical composition
The weight ratio of lactone is 1:0.5.
4. pharmaceutical composition as described in claim 1, which is characterized in that the pharmaceutical preparation comprising pharmaceutical composition is it
Freeze drying powder injection.
5. pharmaceutical composition as claimed in claim 4, which is characterized in that each in the freeze drying powder injection of described pharmaceutical composition
The content of Parecoxib Sodium is 5mg-10mg in unit formulation, and the content of ginkgolides is 0.5-5mg.
6. pharmaceutical composition as claimed in claim 4, which is characterized in that drug in the freeze drying powder injection of described pharmaceutical composition
Acceptable auxiliary material is mannitol, water for injection, sodium chloride, sodium citrate, dextran, disodium hydrogen phosphate, sodium dihydrogen phosphate
In one or more.
7. pharmaceutical composition as claimed in claim 4, which is characterized in that the 1000 of the freeze drying powder injection of described pharmaceutical composition
It is prepared in a preparation unit by following component：
8. pharmaceutical composition as claimed in claim 4, which is characterized in that the system of the freeze drying powder injection of the pharmaceutical composition
Preparation Method includes the following steps：It weighs Parecoxib Sodium, ginkgolides and auxiliary material respectively by recipe quantity, auxiliary material is added in right amount
In water for injection, stirring and dissolving and with 0.1% activated carbon adsorption, 0.45 μm of filter or filter membrane pre-filtering adds in Parecoxib Sodium
Stirring and dissolving simultaneously adjusts pH value to 7.0-8.5 with sodium hydroxide, constant volume after 0.45 μm of filter or filter membrane pre-filtering, 0.45 μm and
Filling after 0.22 μm of filter or filter membrane aseptic filtration, half tamponade is freeze-dried to obtain the freeze-dried powder of the present composition
Injection.
9. purposes of the pharmaceutical composition described in claim 1 in analgesic is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810137367.6A CN108066339B (en) | 2018-02-10 | 2018-02-10 | A kind of pharmaceutical composition of Parecoxib Sodium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810137367.6A CN108066339B (en) | 2018-02-10 | 2018-02-10 | A kind of pharmaceutical composition of Parecoxib Sodium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108066339A true CN108066339A (en) | 2018-05-25 |
| CN108066339B CN108066339B (en) | 2018-12-14 |
Family
ID=62155101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810137367.6A Active CN108066339B (en) | 2018-02-10 | 2018-02-10 | A kind of pharmaceutical composition of Parecoxib Sodium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108066339B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112979572A (en) * | 2020-11-24 | 2021-06-18 | 苏州璞正医药有限公司 | Parecoxib derivative and preparation method and application thereof |
| EP3932397A4 (en) * | 2019-03-01 | 2022-12-07 | Eurofarma Laboratórios S.A. | Non-steroidal anti-inflammatory lyophilized pharmaceutical composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007054789A1 (en) * | 2005-11-08 | 2007-05-18 | Ranbaxy Laboratories Limited | Pharmaceutical combination comprising atorvastatin derivatives |
| CN102068426A (en) * | 2009-11-24 | 2011-05-25 | 秦引林 | New application of Ginkgolide B derivative in medicament preparation |
| CN102512383A (en) * | 2011-12-25 | 2012-06-27 | 天津市嵩锐医药科技有限公司 | Parecoxib sodium pharmaceutical composition for injection |
-
2018
- 2018-02-10 CN CN201810137367.6A patent/CN108066339B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007054789A1 (en) * | 2005-11-08 | 2007-05-18 | Ranbaxy Laboratories Limited | Pharmaceutical combination comprising atorvastatin derivatives |
| CN102068426A (en) * | 2009-11-24 | 2011-05-25 | 秦引林 | New application of Ginkgolide B derivative in medicament preparation |
| CN102512383A (en) * | 2011-12-25 | 2012-06-27 | 天津市嵩锐医药科技有限公司 | Parecoxib sodium pharmaceutical composition for injection |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3932397A4 (en) * | 2019-03-01 | 2022-12-07 | Eurofarma Laboratórios S.A. | Non-steroidal anti-inflammatory lyophilized pharmaceutical composition |
| CN112979572A (en) * | 2020-11-24 | 2021-06-18 | 苏州璞正医药有限公司 | Parecoxib derivative and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108066339B (en) | 2018-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Waterman et al. | Interstitial fluid and serum antibiotic concentrations | |
| Zeng et al. | Pharmacokinetics and safety of ginsenoside Rd following a single or multiple intravenous dose in healthy Chinese volunteers | |
| EP2862575B1 (en) | Application of piceatannol-3'-o-b-d-glucopyranoside in preparation of medicaments for improving microcirculation block | |
| Basu et al. | Preparation and characterisation of mucoadhesive nasal gel of venlafaxine hydrochloride for treatment of anxiety disorders | |
| CN108057018A (en) | Colchicin topical composition and preparation method thereof | |
| CN108066339B (en) | A kind of pharmaceutical composition of Parecoxib Sodium | |
| CN101288648A (en) | Easy-to-administrate oxiracetam granular formulation and preparation method | |
| Sampaopan et al. | Formulation development and pharmaceutical evaluation of Lysiphyllum strychnifolium topical patches for their anti-inflammatory potential | |
| CN104546928B (en) | A kind of Chinese medicine composition and preparation method thereof for treating infant diaper rash | |
| CN103239586A (en) | Flavored agastache turbidity-dispelling external preparation as well as preparation method and application thereof | |
| CN107519136A (en) | A kind of Choline Chloride Succinate lyophilized formulations and preparation method thereof | |
| CN108785299A (en) | Glabridin is preparing the application in treating thrombotic diseases drug | |
| CN107970245A (en) | Three kinds of root of Beijing euphorbia alkane type triterpenoids are used to prepare Gli gene inhibitors and prevent the biomedical uses of liver-cancer medicine | |
| CN103520186B (en) | Pharmaceutical composition of a kind of fat-soluble vitamin for injection and preparation method thereof | |
| CN106177962A (en) | Pharmaceutical composition containing Sarpogrelate is for treating or prevent the purposes of fatty liver, hepatic fibrosis and/or hepatic injury | |
| CN107157924A (en) | Naproxen sodium sodium chloride injection and preparation method thereof | |
| CN106806376A (en) | The pharmaceutical composition of paracetamol and glycyrrhizic acid or its salt or derivatives thereof | |
| CN104922677B (en) | A kind of pharmaceutical composition of hydrochloric stephanine is preparing the application in treating leukopenic drug | |
| CN107569465A (en) | A kind of Nifedipine sustained release tablets and preparation method thereof | |
| CN102688188A (en) | maleic acid cinepazide injection and preparation method thereof | |
| CN107260720A (en) | Application of the casticin in medicament for resisting ulcerative colitis is prepared | |
| CN107669700A (en) | A kind of medicine for treating ulcerative colitis and preparation method thereof | |
| CN110898042B (en) | Salbutamol sulfate solution for inhalation and preparation method thereof | |
| CN105343036B (en) | GM H medical usage and its pharmaceutical composition | |
| CN101647793B (en) | Application of anacardic acid in preparing anti-angiogenic drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |